These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

321 related articles for article (PubMed ID: 27114562)

  • 1. Prediction of remission and low disease activity in disease-modifying anti-rheumatic drug-refractory patients with rheumatoid arthritis treated with golimumab.
    Vastesaeger N; Kutzbach AG; Amital H; Pavelka K; Lazaro MA; Moots RJ; Wollenhaupt J; Zerbini CA; Louw I; Combe B; Beaulieu A; Schulze-Koops H; Dasgupta B; Fu B; Huyck S; Weng HH; Govoni M; Durez P
    Rheumatology (Oxford); 2016 Aug; 55(8):1466-76. PubMed ID: 27114562
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Remission and low disease activity matrix tools: results in real-world rheumatoid arthritis patients under anti-TNF therapy.
    Ganhão S; Lucas R; Fonseca JE; Santos MJ; Gonçalves DR; Madeira N; Silva C; Dourado E; Freitas R; Rodrigues J; Azevedo S; Rocha TM; Ferreira RM; Garcia S; Fernandes BM; Prata AR; Couto M; Torres RP; Cunha I; Costa L; Bernardes M
    Acta Reumatol Port; 2020; 45(4):245-252. PubMed ID: 33420771
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Patient and physician expectations of add-on treatment with golimumab for rheumatoid arthritis: relationships between expectations and clinical and quality of life outcomes.
    Dasgupta B; Combe B; Louw I; Wollenhaupt J; Zerbini CA; Beaulieu A; Schulze-Koops H; Durez P; Wolff V; Yao R; Weng HH; Govoni M; Vastesaeger N
    Arthritis Care Res (Hoboken); 2014 Dec; 66(12):1799-807. PubMed ID: 24839031
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Predictors, demographics and frequency of sustained remission and low disease activity in anti-tumour necrosis factor-treated rheumatoid arthritis patients.
    Hamann PDH; Pauling JD; McHugh N; Shaddick G; Hyrich K;
    Rheumatology (Oxford); 2019 Dec; 58(12):2162-2169. PubMed ID: 31155669
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of golimumab in Indian patients with rheumatoid arthritis: Subgroup data from GO-MORE study.
    Pal S; Veeravalli SC; Das SK; Shobha V; Uppuluri RR; Dharmanand BG; Nadkar M; Hsia E; Fei K; Yao R; Khalifa A
    Int J Rheum Dis; 2016 Nov; 19(11):1083-1092. PubMed ID: 27457311
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical predictors of remission and low disease activity in Latin American early rheumatoid arthritis: data from the GLADAR cohort.
    Gamboa-Cárdenas RV; Ugarte-Gil MF; Loreto M; Sacnun MP; Saurit V; Cardiel MH; Soriano ER; Pisoni C; Galarza-Maldonado CM; Rios C; Radominski SC; Castelar-Pinheiro GDR; Bianchi WA; Appenzeller S; da Silveira IG; de Freitas Zerbini CA; Caballero-Uribe CV; Rojas-Villarraga A; Guibert-Toledano M; Ballesteros F; Montufar R; Vázquez-Mellado J; Esquivel-Valerio J; De La Torre IG; Barile-Fabris LA; Palezuelos FI; Andrade-Ortega L; Monge P; Teijeiro R; Achurra-Castillo ÁF; Esteva Spinetti MH; Alarcón GS; Pons-Estel BA
    Clin Rheumatol; 2019 Oct; 38(10):2737-2746. PubMed ID: 31161486
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical remission and/or minimal disease activity in patients receiving adalimumab treatment in a multinational, open-label, twelve-week study.
    Burmester GR; Ferraccioli G; Flipo RM; Monteagudo-Sáez I; Unnebrink K; Kary S; Kupper H
    Arthritis Rheum; 2008 Jan; 59(1):32-41. PubMed ID: 18163417
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of golimumab as add-on therapy to disease-modifying antirheumatic drugs: results of the GO-MORE study.
    Combe B; Dasgupta B; Louw I; Pal S; Wollenhaupt J; Zerbini CA; Beaulieu AD; Schulze-Koops H; Durez P; Yao R; Vastesaeger N; Weng HH;
    Ann Rheum Dis; 2014 Aug; 73(8):1477-86. PubMed ID: 23740226
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of golimumab as add-on therapy to disease-modifying antirheumatic drugs in rheumatoid arthritis: results of the GO-MORE study in Spain.
    Alonso A; González CM; Ballina J; García Vivar ML; Gómez-Reino JJ; Marenco JL; Fernández-Nebro A; Ordás C; Cea-Calvo L; Arteaga MJ; Sanmartí R
    Reumatol Clin; 2015; 11(3):144-50. PubMed ID: 25022442
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Physician global assessment at 3 months is strongly predictive of remission at 12 months in early rheumatoid arthritis: results from the CATCH cohort.
    Choy T; Bykerk VP; Boire G; Haraoui BP; Hitchon C; Thorne C; Keystone EC; Pope JE;
    Rheumatology (Oxford); 2014 Mar; 53(3):482-90. PubMed ID: 24241035
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Discordance between tender and swollen joint count as well as patient's and evaluator's global assessment may reduce likelihood of remission in patients with rheumatoid arthritis and psoriatic arthritis: data from the prospective multicentre NOR-DMARD study.
    Michelsen B; Kristianslund EK; Hammer HB; Fagerli KM; Lie E; Wierød A; Kalstad S; Rødevand E; Krøll F; Haugeberg G; Kvien TK
    Ann Rheum Dis; 2017 Apr; 76(4):708-711. PubMed ID: 27707730
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Structural and functional outcomes of a therapeutic strategy targeting low disease activity in patients with elderly-onset rheumatoid arthritis: a prospective cohort study (CRANE).
    Sugihara T; Ishizaki T; Hosoya T; Iga S; Yokoyama W; Hirano F; Miyasaka N; Harigai M
    Rheumatology (Oxford); 2015 May; 54(5):798-807. PubMed ID: 25296748
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Predictors of response to anti-TNF-alpha therapy among patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register.
    Hyrich KL; Watson KD; Silman AJ; Symmons DP;
    Rheumatology (Oxford); 2006 Dec; 45(12):1558-65. PubMed ID: 16705046
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Good clinical response, remission, and predictors of remission in rheumatoid arthritis patients treated with tumor necrosis factor-alpha blockers: the GISEA study.
    Mancarella L; Bobbio-Pallavicini F; Ceccarelli F; Falappone PC; Ferrante A; Malesci D; Massara A; Nacci F; Secchi ME; Manganelli S; Salaffi F; Bambara ML; Bombardieri S; Cutolo M; Ferri C; Galeazzi M; Gerli R; Giacomelli R; Grassi W; Lapadula G; Cerinic MM; Montecucco C; Trotta F; Triolo G; Valentini G; Valesini G; Ferraccioli GF;
    J Rheumatol; 2007 Aug; 34(8):1670-3. PubMed ID: 17611987
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Maintenance of efficacy and safety with subcutaneous golimumab in rheumatoid arthritis patients with low disease activity who previously received TNF inhibitors.
    Wakabayashi H; Inada H; Nishioka Y; Hasegawa M; Sudo A; Nishioka K
    Clin Rheumatol; 2017 Apr; 36(4):941-946. PubMed ID: 27942977
    [TBL] [Abstract][Full Text] [Related]  

  • 16. How much does Disease Activity Score in 28 joints ESR and CRP calculations underestimate disease activity compared with the Simplified Disease Activity Index?
    Fleischmann R; van der Heijde D; Koenig AS; Pedersen R; Szumski A; Marshall L; Bananis E
    Ann Rheum Dis; 2015 Jun; 74(6):1132-7. PubMed ID: 25143522
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Factors Predicting 2 Years of Remission and Low Disease Activity in Rheumatoid Arthritis Patients Treated with TNF-inhibitors.
    Conigliaro P; Triggianese P; Chimenti MS; Tonelli M; Sunzini F; Kroegler B; Perricone R
    Isr Med Assoc J; 2017 Aug; 19(8):467-472. PubMed ID: 28825763
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of golimumab in Belgian patients with active rheumatoid arthritis despite treatment with non-biologic disease-modifying anti-rheumatic drugs: sub-analysis of the GO-MORE study.
    Durez P; Vanthuyne M; Soyfoo MS; Hoffman I; Malaise M; Geusens P
    Acta Clin Belg; 2017 Dec; 72(6):424-428. PubMed ID: 28431485
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Differences in Predictive Factors for Sustained Clinical Remission with Abatacept Between Younger and Elderly Patients with Biologic-naive Rheumatoid Arthritis: Results from the ABROAD Study.
    Sekiguchi M; Fujii T; Matsui K; Murakami K; Morita S; Ohmura K; Kawahito Y; Nishimoto N; Mimori T; Sano H;
    J Rheumatol; 2016 Nov; 43(11):1974-1983. PubMed ID: 27585689
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Twenty-eight-week results from the REALISTIC phase IIIb randomized trial: efficacy, safety and predictability of response to certolizumab pegol in a diverse rheumatoid arthritis population.
    Weinblatt ME; Fleischmann R; van Vollenhoven RF; Emery P; Huizinga TW; Cutolo M; van der Heijde D; Duncan B; Davies O; Luijtens K; Dougados M
    Arthritis Res Ther; 2015 Nov; 17():325. PubMed ID: 26568428
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.